Floatz logo

Decitabine

Malignant Pleural Mesotheliomas

National Cancer Institute (NCI)Small moleculePhase 1/2Dormant
CCC
55/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
89/ 100

Competitive context

35 Active assets in the Malignant Pleural Mesotheliomas cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
AstraZeneca
Phase 2BB
Carboplatin
AstraZeneca
Phase 2BB
Pembrolizumab
NuCana plc
Phase 2B
FLUOROURACILUM
Memorial Sloan Kettering Cancer Center
Phase 2B
Atezolizumab
Swiss Cancer Institute
Phase 2B

View all 50 →

Same molecule, other indications

Decitabine is also rated in:

disease related to hematopoietic stem cell transplantDormant
BBB
Indicative ·
72 / 100
View asset →
acute myeloid leukemia with t(8;21)(q22;q22) translocationDormant
BB
Indicative ·
70 / 100
View asset →
acute myeloid leukemiaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →